Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exelixis, Inc.

< Previous 1 2 3 4 Next >
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Elects Jacqueline Wright to Its Board of Directors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Statement on the Passing of Two Senior Executives
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.